Bas W. van Rhijn

2.7k total citations
30 papers, 1.2k citations indexed

About

Bas W. van Rhijn is a scholar working on Surgery, Urology and Oncology. According to data from OpenAlex, Bas W. van Rhijn has authored 30 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Surgery, 11 papers in Urology and 6 papers in Oncology. Recurrent topics in Bas W. van Rhijn's work include Bladder and Urothelial Cancer Treatments (26 papers), Urinary and Genital Oncology Studies (22 papers) and Urological Disorders and Treatments (10 papers). Bas W. van Rhijn is often cited by papers focused on Bladder and Urothelial Cancer Treatments (26 papers), Urinary and Genital Oncology Studies (22 papers) and Urological Disorders and Treatments (10 papers). Bas W. van Rhijn collaborates with scholars based in Netherlands, United States and Canada. Bas W. van Rhijn's co-authors include Simon Horenblas, Henk G. van der Poel, Yair Lotan, Renato A. Valdés Olmos, Fijs W. B. van Leeuwen, Oscar R. Brouwer, Bernd J. Schmitz‐Dräger, Michael J. Droller, Pierre I. Karakiewicz and Shahrokh F. Shariat and has published in prestigious journals such as Scientific Reports, The Journal of Urology and Annals of Oncology.

In The Last Decade

Bas W. van Rhijn

29 papers receiving 1.2k citations

Peers

Countries citing papers authored by Bas W. van Rhijn

Since Specialization

Citations

This map shows the geographic impact of Bas W. van Rhijn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bas W. van Rhijn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bas W. van Rhijn more than expected).

Fields of papers citing papers by Bas W. van Rhijn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bas W. van Rhijn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bas W. van Rhijn. The network helps show where Bas W. van Rhijn may publish in the future.

Co-authorship network of co-authors of Bas W. van Rhijn

This figure shows the co-authorship network connecting the top 25 collaborators of Bas W. van Rhijn. A scholar is included among the top collaborators of Bas W. van Rhijn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bas W. van Rhijn. Bas W. van Rhijn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Stage-dependent survival in patients treated with neoadjuvant chemotherapy and radical cystectomy 2023 ·Minerva Urology and Nephrology ·David D‘Andrea, Shahrokh F. Shariat, Francesco Soria, Ettore Di Trapani, Laura S. Mertens, Bas W. van Rhijn, Colin P. Dinney, Peter C. Black, Philippe E. Spiess, (unknown), Benjamin Pradère, Elena Tonin, Renate Pichler, (unknown), Andrea Mari, Marco Moschini	2
2	Evaluation of the Hybrid Tracer Indocyanine Green–99mTc-Nanocolloid for Sentinel Node Biopsy in Bladder Cancer—A Prospective Pilot Study 2022 ·Clinical Nuclear Medicine ·Daphne D. D. Rietbergen, (unknown), Gijs H. KleinJan, Maarten L. Donswijk, Renato A. Valdés Olmos, Bas W. van Rhijn, Henk G. van der Poel, Fijs W. B. van Leeuwen	16
3	Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network 2018 ·Urologic Oncology Seminars and Original Investigations ·Tahlita C.M. Zuiverloon, Kim E.M. van Kessel, Trinity J. Bivalacqua, Joost L. Boormans, Thorsten Ecke, Petros Grivas, Anne E. Kiltie, Fredrik Liedberg, Andrea Necchi, Bas W. van Rhijn, Florian Roghmann, Marta Sänchez‐Carbayo, Bernd J. Schmitz‐Dräger, Felix Wezel, Ashish M. Kamat	16
4	Outcome of sentinel lymph node biopsy in patients with clinically non-metastatic renal cell carcinoma 2018 ·Scandinavian Journal of Urology ·Teele Kuusk, (unknown), Oscar R. Brouwer, Jeroen de Jong, Maarten L. Donswijk, Kees Hendricksen, Simon Horenblas, Katarzyna Jóźwiak, Warner Prevoo, Renato A. Valdés Olmos, H.G. Van Der Poel, Bas W. van Rhijn, Esther Wit, Axel Bex	4
5	Dose dense MVAC prior to radical cystectomy: a real-world experience 2017 ·World Journal of Urology ·Homayoun Zargar, Jay B. Shah, Elisabeth E. Fransen van de Putte, Kylea Potvin, Kamran Zargar‐Shoshtari, Bas W. van Rhijn, Siamak Daneshmand, Jeff M. Holzbeierlein, Philippe E. Spiess, Eric Winquist, Simon Horenblas, Colin P. Dinney, Peter C. Black, Wassim Kassouf	9
6	Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer 2017 ·Scientific Reports ·Keval Patel, Kristan E. van der Vos, Christopher G. Smith, Florent Moulière, Dana W.Y. Tsui, James Morris, Dineika Chandrananda, Francesco Marass, Daan van den Broek, David E. Neal, Vincent J. Gnanapragasam, Tim Forshew, Bas W. van Rhijn, Charles Massie, Nitzan Rosenfeld, Michiel S. van der Heijden	84
7	Epigenome-Wide DNA Methylation Profiling Identifies Differential Methylation Biomarkers in High-Grade Bladder Cancer 2017 ·Translational Oncology ·Ekaterina Olkhov‐Mitsel, (unknown), Ken J. Kron, Vaijayanti Pethe, Thomas Hermanns, Neil Fleshner, Bas W. van Rhijn, Theodorus van der Kwast, Alexandre R. Zlotta, Bharati Bapat	26
8	Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer—Does pT0 Predict Better Survival than pTa/Tis/T1? 2015 ·The Journal of Urology ·Homayoun Zargar, Kamran Zargar‐Shoshtari, Yair Lotan, Jay B. Shah, Bas W. van Rhijn, Siamak Daneshmand, Philippe E. Spiess, Peter C. Black, (unknown)	52
9	Molecular Markers for Bladder Cancer Screening, Early Diagnosis, and Surveillance: The WHO/ICUD Consensus 2014 ·Urologia Internationalis ·Bernd J. Schmitz‐Dräger, Michael J. Droller, Vinata B. Lokeshwar, Yair Lotan, M’Liss A. Hudson, Bas W. van Rhijn, Michael Marberger, Yves Fradet, George P. Hemstreet, Per‐Uno Malmström, Osamu Ogawa, Pierre I. Karakiewicz, Shahrokh F. Shariat	118
10	A Hybrid Radioactive and Fluorescent Tracer for Sentinel Node Biopsy in Penile Carcinoma as a Potential Replacement for Blue Dye 2013 ·European Urology ·Oscar R. Brouwer, Nynke S. van den Berg, Hanna M. Mathéron, Henk G. van der Poel, Bas W. van Rhijn, Axel Bex, Harm van Tinteren, Renato A. Valdés Olmos, Fijs W. B. van Leeuwen, Simon Horenblas	114
11	Response to induction chemotherapy and surgery in non-organ confined bladder cancer: A single institution experience 2013 ·European Journal of Surgical Oncology ·Richard P. Meijer, Jakko A. Nieuwenhuijzen, Wim Meinhardt, A. Bex, Henk G. van der Poel, Bas W. van Rhijn, J. Martijn Kerst, Andries M. Bergman, Erik van Werkhoven, Simon Horenblas	21
12	Impact of ¹⁸ F ‐fluorodeoxyglucose ( FDG )‐positron‐emission tomography/computed tomography ( PET / CT ) on management of patients with carcinoma invading bladder muscle 2013 ·British Journal of Urology ·Laura S. Mertens, (unknown), Erik Vegt, Wouter V. Vogel, Bas W. van Rhijn, Simon Horenblas	50
13	Induction Chemotherapy Followed by Surgery in Node Positive Bladder Cancer 2013 ·Urology ·Richard P. Meijer, Laura S. Mertens, Bas W. van Rhijn, Axel Bex, Henk G. van der Poel, Wim Meinhardt, J. Martijn Kerst, Andries M. Bergman, (unknown), Erik van Werkhoven, Simon Horenblas	40
14	Catheter-assisted 18F-FDG-PET/CT imaging of primary bladder cancer 2012 ·Nuclear Medicine Communications ·Laura S. Mertens, (unknown), Erik Vegt, (unknown), (unknown), Bas W. van Rhijn, Simon Horenblas, Wouter V. Vogel	20
15	ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, Diagnosis, and Molecular Markers 2012 ·European Urology ·Ashish M. Kamat, Paul K. Hegarty, Jason Gee, Peter E. Clark, Robert S. Svatek, Nicholas J. Hegarty, Shahrokh F. Shariat, Évanguelos Xylinas, Bernd J. Schmitz‐Dräger, Yair Lotan, Lawrence C. Jenkins, Michael J. Droller, Bas W. van Rhijn, Pierre I. Karakiewicz	208
16	Differences in histopathological evaluation of standard lymph node dissections result in differences in nodal count but not in survival 2012 ·World Journal of Urology ·Laura S. Mertens, Richard P. Meijer, Erik van Werkhoven, Axel Bex, Henk G. van der Poel, Bas W. van Rhijn, W. Meinhardt, Simon Horenblas	8
17	Comparing the Hybrid Fluorescent–Radioactive Tracer Indocyanine Green–^99mTc-Nanocolloid with ^99mTc-Nanocolloid for Sentinel Node Identification: A Validation Study Using Lymphoscintigraphy and SPECT/CT 2012 ·Journal of Nuclear Medicine ·Oscar R. Brouwer, Tessa Buckle, Lenka Vermeeren, W. Martin C. Klop, Alfons J. M. Balm, Henk G. van der Poel, Bas W. van Rhijn, Simon Horenblas, Omgo E. Nieweg, Fijs W. B. van Leeuwen, Renato A. Valdés Olmos	163
18	CYSTOSCOPY REVISITED AS THE GOLD STANDARD FOR DETECTION OF BLADDER CANCER RECURRENCE: DIAGNOSTIC REVIEW BIAS IN A RANDOMISED PROSPECTIVE TRIAL 2009 ·The Journal of Urology ·(unknown), Ewout W. Steyerberg, Chris H. Bangma, Bas W. van Rhijn, Ellen C. Zwarthoff, Theodorus van der Kwast	1
19	THE FGFR3 MUTATION IS RELATED TO FAVORABLE PT1 BLADDER CANCER 2009 ·The Journal of Urology ·Bas W. van Rhijn, Bharati Bapat, Theodorus van der Kwast, Liyang Liu, Neil Fleshner, (unknown), (unknown), Chris H. Bangma, Ellen C. Zwarthoff, Michael Jewett, Alexandre R. Zlotta	6
20	Non‐muscle‐invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost‐effective alternative? 2008 ·British Journal of Urology ·Esther W. de Bekker‐Grob, Madelon N.M. van der Aa, Ellen C. Zwarthoff, Marinus J.C. Eijkemans, Bas W. van Rhijn, Theodorus van der Kwast, Ewout W. Steyerberg	36

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact